Over the past decade, targeted therapies, such as inhibitors of Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 anti-apoptotic protein-2 (Bcl-2), have revolutionized the management of CLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.